Analysts Set C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target at $10.67

C4 Therapeutics, Inc. (NASDAQ:CCCC) has been given an average rating of “Moderate Buy” by the six ratings firms that are covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $10.67.

CCCC has been the subject of several recent analyst reports. Wells Fargo & Company raised C4 Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $8.00 to $12.00 in a research report on Thursday, December 19th. Stephens began coverage on C4 Therapeutics in a report on Monday, November 18th. They set an “equal weight” rating and a $4.00 price objective for the company.

Institutional Trading of C4 Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CCCC. Headlands Technologies LLC bought a new position in C4 Therapeutics during the second quarter valued at about $45,000. B. Riley Wealth Advisors Inc. bought a new position in C4 Therapeutics during the second quarter valued at about $51,000. Point72 DIFC Ltd bought a new position in C4 Therapeutics during the third quarter valued at about $51,000. Cynosure Group LLC bought a new position in C4 Therapeutics during the third quarter valued at about $57,000. Finally, Aigen Investment Management LP bought a new position in C4 Therapeutics during the third quarter valued at about $82,000. 78.81% of the stock is currently owned by hedge funds and other institutional investors.

C4 Therapeutics Stock Down 4.5 %

CCCC opened at $3.86 on Tuesday. The firm has a market cap of $272.48 million, a PE ratio of -2.27 and a beta of 2.96. The business has a fifty day simple moving average of $4.23 and a 200-day simple moving average of $5.35. C4 Therapeutics has a fifty-two week low of $3.38 and a fifty-two week high of $11.88.

C4 Therapeutics (NASDAQ:CCCC) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.05. The business had revenue of $15.36 million during the quarter, compared to analyst estimates of $5.95 million. C4 Therapeutics had a negative return on equity of 42.45% and a negative net margin of 313.35%. On average, equities research analysts anticipate that C4 Therapeutics will post -1.52 EPS for the current fiscal year.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.